Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 73
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
2.
Eur J Clin Microbiol Infect Dis ; 40(10): 2211-2215, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33709301

RESUMEN

Management of cystic fibrosis (CF) patients colonized with Pseudomonas aeruginosa is challenging due to its virulence and multi-drug resistance. Ceftolozane/tazobactam (C/T) is a promising new antipseudomonal agent, and clinical data on CF are limited. We describe our experience in the use of C/T for P. aeruginosa-related pulmonary exacerbations (PE) in CF adults admitted within 2016 and 2019 at Careggi Hospital, Florence, Italy. PE was diagnosed as deterioration of respiratory function, worsening cough, and increasing of sputum. C/T was given at the dose of 3 g every 8 h. C/T was used in ten patients. Mean length of C/T treatment was 16.3 days, and tobramycin was the most frequently combined antipseudomonal agent. All patients were successfully treated although susceptibility testing on sputum sample showed C/T resistance in two cases. No adverse effects related to C/T were reported. To our knowledge this is the largest case series on CF patients treated with C/T. Clinical responses were encouraging even where C/T resistant P. aeruginosa was isolated, probably due to multiple phenotypes colonizing CF lungs. C/T could play a promising role in combination therapy against P. aeruginosa as a part of a colistin-sparing regime.


Asunto(s)
Antibacterianos/uso terapéutico , Cefalosporinas/uso terapéutico , Fibrosis Quística/tratamiento farmacológico , Pulmón/microbiología , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/efectos de los fármacos , Tazobactam/uso terapéutico , Adolescente , Adulto , Fibrosis Quística/microbiología , Humanos , Italia , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/genética , Pseudomonas aeruginosa/aislamiento & purificación , Pseudomonas aeruginosa/fisiología , Esputo/microbiología , Adulto Joven
3.
Clin Exp Rheumatol ; 38(2): 245-256, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31498077

RESUMEN

OBJECTIVES: To provide evidence-based recommendations for vaccination against influenza virus and S. pneumoniae in patients with autoimmune rheumatic diseases (ARDs). METHODS: A Consensus Committee including physicians with expertise in rheumatic and infectious diseases was established by two Italian scientific societies, Società Italiana di Reumatologia (SIR) and Società Italiana di Malattie Infettive e Tropicali (SIMIT). The experts were invited to develop evidence-based recommendations concerning vaccinations in ARDs patients, based on their clinical status before and after undergoing immunosuppressive treatments. Key clinical questions were formulated for the systematic literature reviews, based on the clinical pathway. A search was made in Medline (via PubMed) according to the original MeSH strategy from October 2009 and a keyword strategy from January 2016 up to December 2017, updating existing EULAR recommendations. Specific recommendations were separately voted and scored from 0 (no agreement with) to 100 (maximal agreement) and supporting evidence graded. The mean and standard deviation of the scores were calculated to determine the level of agreement among the experts' panel for each recommendation. Total cumulative agreement ≥70 defined consensus for each statement. RESULTS: Nine recommendations, based on 6 key clinical questions addressed by the expert committee, were proposed. The aim of this work is to integrate the 2011 EULAR recommendations on vaccination against influenza and S. pneumoniae in ARDs patients. An implementation plan was proposed to improve the vaccination status of these patients and their safety during immunosuppressive treatments. CONCLUSIONS: Influenza and pneumococcus vaccinations are effective and safe in patients with ARDs. More efforts should be made to translate the accumulated evidence into practice.


Asunto(s)
Vacunas contra la Influenza/administración & dosificación , Vacunas Neumococicas/administración & dosificación , Enfermedades Reumáticas/inmunología , Vacunación , Adulto , Enfermedades Autoinmunes/complicaciones , Enfermedades Autoinmunes/tratamiento farmacológico , Consenso , Medicina Basada en la Evidencia/métodos , Femenino , Humanos , Inmunosupresores/efectos adversos , Vacunas contra la Influenza/inmunología , Gripe Humana/inmunología , Gripe Humana/prevención & control , Italia , Masculino , Vacunas Neumococicas/inmunología , Neumonía Estafilocócica/inmunología , Neumonía Estafilocócica/prevención & control , Enfermedades Reumáticas/complicaciones , Enfermedades Reumáticas/tratamiento farmacológico , Vacunación/normas
4.
Euro Surveill ; 25(17)2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32372754

RESUMEN

We analysed the first 84 coronavirus disease (COVID-19) patients hospitalised in an infectious and tropical disease unit in Florence, Italy, over 30 days after the start of the COVID-19 outbreak in Italy. A 12% reduction in the rate of intensive care unit transfer was observed after the implementation of intensity care measures in the regular ward such as increasing the nurse/patient ratio, presence of critical care physicians and using high flow nasal cannulae oxygenation.


Asunto(s)
Infecciones por Coronavirus/mortalidad , Infecciones por Coronavirus/terapia , Coronavirus , Unidades de Cuidados Intensivos/organización & administración , Pandemias , Neumonía Viral/mortalidad , Neumonía Viral/terapia , Distribución por Edad , Anciano , Betacoronavirus , COVID-19 , Cánula , Estudios de Cohortes , Comorbilidad , Trazado de Contacto , Infecciones por Coronavirus/diagnóstico , Cuidados Críticos , Brotes de Enfermedades , Femenino , Humanos , Italia/epidemiología , Masculino , Persona de Mediana Edad , Transferencia de Pacientes , Neumonía Viral/diagnóstico , Unidades de Cuidados Respiratorios , SARS-CoV-2 , Distribución por Sexo , Resultado del Tratamiento
5.
Eur J Clin Microbiol Infect Dis ; 38(9): 1781-1785, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-31222396

RESUMEN

The study is aimed at retrospectively estimating the percentage of inpatients with severe acute bacterial skin and skin structure infections (ABSSSI) who met the early discharged (ED) criteria adapted from Nathwani et al. (Int J Antimicrob Agents. 2016 Aug;48(2):127-36) and to calculate the number of hospitalization days that could be potentially saved. A retrospective study was conducted in a tertiary care hospital in Florence, Italy. We included all patients admitted for cellulitis and post-surgical infections from 2014 to 2017. Demographic and clinical data were obtained from electronic medical records. We a priori defined the following as a risk factor for non-adherence (RFNA): active or on methadone intravenous drug users, homeless, migrants without health care assistance, and patients who need a caregiver to take prescribed medications. One hundred sixty-two subjects were enrolled. Of them, 94 (58.0%) were male, and 113 (69.7%) had cellulitis/erysipelas. A microbiological isolate was obtained in 51 patients (31.4%); Staphylococcus aureus was the most frequent (47%). Eighty-four (51.8%) were ED suitable, with 258 (49.0%) patient days potentially saved. Among the 78 not ED suitable patients, the most common reason for prolonged length of stay (LOS) was having at least one RFNA (34.6%). Fourteen (18.0%) had one RFNA. Half of the patients admitted in our hospital met the ED criteria with a sparing close to 50% in terms of hospitalization days. Unstable social and personal factors were the most frequent causes for prolonged LOS. In this selected subset of patients, more recent and easier to administer treatments, including long-acting agents, could be proposed.


Asunto(s)
Hospitales de Enseñanza , Alta del Paciente , Piel/microbiología , Infecciones Cutáneas Estafilocócicas/tratamiento farmacológico , Adulto , Anciano , Antibacterianos/uso terapéutico , Estudios Transversales , Registros Electrónicos de Salud , Femenino , Hospitalización , Humanos , Italia , Tiempo de Internación , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Piel/patología , Infecciones Cutáneas Estafilocócicas/microbiología
6.
Radiol Med ; 124(9): 838-845, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-31087215

RESUMEN

PURPOSE: To identify the most frequent radiological findings of pulmonary tuberculosis using CT of the chest, to determine those with the highest degree of correlation, and, if possible, to identify the most suggestive radiological findings for acid-fast bacilli (AFB) positive disease. MATERIALS AND METHODS: The radiological and clinical data of 49 patients submitted to CT during diagnosis were retrospectively analysed. The association between findings was assessed using Fisher's exact test, while correlation at CT scan was evaluated with the Spearman analysis. RESULTS: Bronchiectasis/bronchioloectasis (89.8%), nodule(s) (81.6%), tree-in-bud (TIB), and consolidation (79.6% each) figured among the most common parenchymal findings. Lymphadenopathy (26.5%) was the most common nodal finding. TIB and cavity showed the highest correlation (r = 0.577), followed by TIB and bronchi(olo)ectasis (r = 0.498), TIB and consolidation (r = 0.497), nodule(s), and ground glass opacity (r = 0.488). High correlation was found in only the seven most frequent parenchymal findings. Consolidation, TIB, and cavity were useful to predict the AFB stain positivity. CONCLUSIONS: Our series confirms the extreme heterogeneity of pulmonary tuberculosis. It also proves there are couple of findings which can drive us to the right diagnosis. While a triad of findings predicts AFB positivity, we have not found any predictive sign of AFB negativity; consequently, all patients with suspected imaging and clinical findings for TB should be isolated.


Asunto(s)
Tomografía Computarizada por Rayos X , Tuberculosis Pulmonar/diagnóstico por imagen , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto Joven
7.
Infection ; 46(1): 55-68, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29086355

RESUMEN

PURPOSE: Tubercular prosthetic joint infection (TB-PJI) is an uncommon complication. Lack of evidence of systemic tuberculosis and clinical suspicion could bring a delay in the time of the diagnosis. The aims of this study are to underline the importance of awareness and suspicion of mycobacterial infection in the differential diagnosis in PJI and to evaluate the appropriateness of different therapeutic options. METHODS: Case report and literature review. RESULTS: We report two cases of TB-PJI after total knee arthroplasty in Caucasian patients without prior history of tubercular disease or exposure. In both cases, the diagnosis was obtained years after the onset of symptoms. Despite that, both patients improved during antitubercular treatment (a four-drug regimen consisting of rifampicin, isoniazid, ethambutol, and pyrazinamide for 2 months, followed by rifampicin and isoniazid). Moreover, after an 18-month course of treatment, there was no need for surgical therapy. The result of the literature review allows us to identify 64 cases of TB-PJI. Many differences in both medical and surgical management have been found, among those reviewed cases. CONCLUSIONS: Considering our experience and the literature review, we recommend considering a conservative approach (debridement and adequate antituberculous chemotherapy) as a suitable and safe option.


Asunto(s)
Antituberculosos/uso terapéutico , Artropatías/tratamiento farmacológico , Complicaciones Posoperatorias/diagnóstico , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Tuberculosis/diagnóstico , Tuberculosis/tratamiento farmacológico , Adulto , Artroplastia de Reemplazo de Rodilla , Diagnóstico Diferencial , Femenino , Humanos , Italia , Artropatías/diagnóstico , Artropatías/microbiología , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/tratamiento farmacológico , Complicaciones Posoperatorias/microbiología , Infecciones Relacionadas con Prótesis/diagnóstico , Infecciones Relacionadas con Prótesis/microbiología , Resultado del Tratamiento , Tuberculosis/microbiología
8.
Infection ; 46(4): 469-476, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-29654496

RESUMEN

PURPOSE: An early adequate antifungal therapy based on the knowledge of local epidemiology can reduce the candidemia-attributable mortality and the length of hospitalization. We performed a retrospective study to analyze the epidemiology of candidemia and the antifungal consumption in our hospital. METHODS: We analyzed Candida spp. isolated from the blood, and their susceptibility profile from 2005 to 2016 in Careggi University Hospital, Florence, Italy. We also performed a stratified analysis by clinical setting where Candida spp. were isolated (Medical Wards, Surgery, Intensive Care Unit-ICU). Then, we retrospectively reviewed the annual consumption of antifungal agents and calculated the defined daily dosing for 10,000 hospital days. RESULTS: The rate of candidemia was higher in ICU than other settings and Candida albicans was the first cause of candidemia (61.2%). After adjustment for hospital days, the rate of C. albicans showed a statistically significant parabolic trend (p < 0.001), with a peak of incidence in 2010. After 2010, we observed a reduction of candidemia due to both C. albicans and non-albicans species. Between 2005 and 2015, we reported an increasing increased use of echinocandins. As far as resistance profile is concerned, only one Candida glabrata isolate was resistant to caspofungin (1.9%) and 30% of C. glabrata were resistant to fluconazole. CONCLUSIONS: Our data describe C. albicans as the first cause of candidemia in all the studied settings and the low rate of echinocandin resistance, despite their increased use over the study period. ICU was confirmed as the setting with the highest incidence of candidemia.


Asunto(s)
Programas de Optimización del Uso de los Antimicrobianos , Candidemia/epidemiología , Centros de Atención Terciaria , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Programas de Optimización del Uso de los Antimicrobianos/estadística & datos numéricos , Candida/clasificación , Candida/efectos de los fármacos , Candida/aislamiento & purificación , Candidemia/tratamiento farmacológico , Candidemia/microbiología , Candidemia/mortalidad , Femenino , Estudios de Seguimiento , Humanos , Italia/epidemiología , Tiempo de Internación , Masculino , Pruebas de Sensibilidad Microbiana , Estudios Retrospectivos
9.
Circ J ; 82(6): 1688-1698, 2018 05 25.
Artículo en Inglés | MEDLINE | ID: mdl-29576595

RESUMEN

BACKGROUND: The therapeutic efficacy of bone marrow mononuclear cells (BM-MNC) autotransplantation in critical limb ischemia (CLI) has been reported. Variable proportions of circulating monocytes express low levels of CD34 (CD14+CD34lowcells) and behave in vitro as endothelial progenitor cells (EPCs). The aim of the present randomized clinical trial was to compare the safety and therapeutic effects of enriched circulating EPCs (ECEPCs) with BM-MNC administration.Methods and Results:ECEPCs (obtained from non-mobilized peripheral blood by immunomagnetic selection of CD14+and CD34+cells) or BM-MNC were injected into the gastrocnemius of the affected limb in 23 and 17 patients, respectively. After a mean of 25.2±18.6-month follow-up, both groups showed significant and progressive improvement in muscle perfusion (primary endpoint), rest pain, consumption of analgesics, pain-free walking distance, wound healing, quality of life, ankle-brachial index, toe-brachial index, and transcutaneous PO2. In ECEPC-treated patients, there was a positive correlation between injected CD14+CD34lowcell counts and the increase in muscle perfusion. The safety profile was comparable between the ECEPC and BM-MNC treatment arms. In both groups, the number of deaths and major amputations was lower compared with eligible untreated patients and historical reference patients. CONCLUSIONS: This study supports previous trials showing the efficacy of BM-MNC autotransplantation in CLI patients and demonstrates comparable therapeutic efficacy between BM-MNC and EPEPCs.


Asunto(s)
Trasplante de Médula Ósea/métodos , Células Progenitoras Endoteliales/trasplante , Isquemia/terapia , Trasplante Autólogo/métodos , Anciano , Amputación Quirúrgica , Células de la Médula Ósea , Trasplante de Médula Ósea/normas , Extremidades/patología , Femenino , Humanos , Leucocitos Mononucleares/trasplante , Masculino , Persona de Mediana Edad , Análisis de Supervivencia , Trasplante Autólogo/normas
10.
Euro Surveill ; 23(41)2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30326993

RESUMEN

In August 2018 a Moroccan man living in Tuscany developed Plasmodium falciparum malaria. The patient declared having not recently visited any endemic country, leading to diagnostic delay and severe malaria. As susceptibility to P. falciparum of Anopheles species in Tuscany is very low, and other risk factors for acquiring malaria could not be completely excluded, the case remains cryptic, similar to other P. falciparum malaria cases previously reported in African individuals living in Apulia in 2017.


Asunto(s)
Malaria Falciparum/diagnóstico , Plasmodium falciparum/aislamiento & purificación , Administración Intravenosa , Administración Oral , Antimaláricos/administración & dosificación , Antimaláricos/uso terapéutico , Artemisininas/administración & dosificación , Artemisininas/uso terapéutico , Artesunato/administración & dosificación , Artesunato/uso terapéutico , Humanos , Italia , Malaria Falciparum/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Marruecos , Quinolinas/administración & dosificación , Quinolinas/uso terapéutico , Migrantes , Resultado del Tratamiento
11.
Clin Exp Rheumatol ; 35(5): 752-765, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28516869

RESUMEN

OBJECTIVES: Inflammatory arthritis needs infectious disease screening before starting a biologic agent, however, few data are known about migrant patients, who represent a peculiar population which requires a multidisciplinary approach among international health specialists and should also be considered by health authorities. For this reason, the Italian and Spanish Societies of Rheumatology (SIR and SER) and Tropical Medicine (SIMET and SEMTSI) promoted a multidisciplinary task force in order to produce specific recommendations about screening and advices to be considered in migrant patients with inflammatory arthritis candidate to receive biological therapy, according to their geographical origin. METHODS: The experts provided a prioritised list of research questions and the eligible spectrum of inflammatory arthritis, biologic drugs and infectious disease were defined in order to perform a systematic literature review. A search was made in Medline, Embase and Cochrane library, updated to March 2015. Ubiquitous infections and HBV, HCV, HIV and tuberculosis that are already considered in national and international recommendations, were not included. The strength of each recommendation was determined. RESULTS: The task force members agreed on 7 overarching principles. The risk of reactivation of selected potentially latent infectious disease was addressed in migrants with inflammatory arthritis candidates for biologics was considered and 15 potentially relevant infections were identified. CONCLUSIONS: Fifteen disease-specific recommendations were formulated on the basis of high level of agreement among the experts panel.


Asunto(s)
Comités Consultivos , Artritis Reumatoide/tratamiento farmacológico , Productos Biológicos/uso terapéutico , Enfermedades Transmisibles/diagnóstico , Emigrantes e Inmigrantes , Emigración e Inmigración , Infectología/normas , Tamizaje Masivo/normas , Reumatología/normas , Sociedades Médicas , Artritis Reumatoide/diagnóstico , Artritis Reumatoide/etnología , Productos Biológicos/efectos adversos , Enfermedades Transmisibles/etnología , Consenso , Medicina Basada en la Evidencia/normas , Humanos , Italia/epidemiología , Tamizaje Masivo/métodos , Valor Predictivo de las Pruebas , Medición de Riesgo , Factores de Riesgo , España/epidemiología
12.
J Clin Microbiol ; 54(7): 1851-1854, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-27170017

RESUMEN

Microbiological tests on cerebrospinal fluid (CSF) utilize a common urgent-care procedure that does not take into account the chemical and cytological characteristics of the CSF, resulting sometimes in an unnecessary use of human and diagnostic resources. The aim of this study was to retrospectively validate a simple scoring system (bacterial meningitis-Careggi score [BM-CASCO]) based on blood and CSF sample chemical/cytological parameters for evaluating the probability of acute bacterial meningitis (ABM) in adults. BM-CASCO (range, 0 to 6) was defined by the following parameters: CSF cell count, CSF protein levels, CSF lactate levels, CSF glucose-to-serum glucose ratio, and peripheral neutrophil count. BM-CASCO was retrospectively calculated for 784 cases of suspected ABM in adult subjects observed during a four-and-a-half-year-period (2010 to 2014) at the emergency department (ED) of a large tertiary-care teaching hospital in Italy. Among the 28 confirmed ABM cases (3.5%), Streptococcus pneumoniae was the most frequent cause (16 cases). All ABM cases showed a BM-CASCO value of ≥3. Most negative cases (591/756) exhibited a BM-CASCO value of ≤1, which was adopted in our laboratory as a cutoff to not proceed with urgent microbiological analysis of CSF in cases of suspected ABM in adults. During a subsequent 1-year follow-up, the introduction of the BM-CASCO in the diagnostic workflow of ABM in adults resulted in a significant decrease in unnecessary microbiological analysis, with no false negatives. In conclusion, BM-CASCO appears to be an accurate and simple scoring system for optimization of the microbiological diagnostic workflow of ABM in adults.


Asunto(s)
Técnicas de Laboratorio Clínico/métodos , Técnicas de Apoyo para la Decisión , Pruebas Diagnósticas de Rutina/métodos , Meningitis Bacterianas/diagnóstico , Flujo de Trabajo , Adulto , Anciano , Anciano de 80 o más Años , Células Sanguíneas , Líquido Cefalorraquídeo/química , Líquido Cefalorraquídeo/citología , Femenino , Humanos , Italia , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto Joven
13.
New Microbiol ; 39(2): 156-9, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27196558

RESUMEN

Madura foot is a chronic granulomatous infection of the soft-tissue of the foot and it is endemic in tropical and subtropical countries. Some cases have also been reported in local people or migrants in temperate countries. The microbiological diagnosis requires prolonged bacterial cultures in aerobic and anaerobic conditions, but the use of the molecular approach could be helpful for an early and rapid diagnosis. We describe an autochthonous case of Actinomadura madurae foot infection in an Italian woman. The diagnosis was achieved 36 months after symptoms onset by PCR detection and sequencing of 16S rDNA directly on biopsy. She started therapy with rifampin, trimethoprim-sulfamethoxazole, and amikacin. After 3 months the pain had disappeared and the swelling subsided. We reviewed the literature on Madura foot due to bacterial causative agents in Europe and observed that the median time from onset to diagnosis is high, possibly due to several factors like the difficulties of the microbiological and radiological diagnosis. Our case report and the review of literature point out that the implementation of a surveillance system, the involvement of an infectious diseases specialist, with experience in tropical diseases, and the availability of a microbiology unit to perform feasible and rapid molecular diagnostic tests could result in an earlier diagnosis and an optimal antibiotic therapy of this rare but difficult-to-treat and, above all, difficult-to-diagnose infection.


Asunto(s)
Micetoma/diagnóstico , Actinobacteria/aislamiento & purificación , Europa (Continente)/epidemiología , Femenino , Humanos , Persona de Mediana Edad , Micetoma/epidemiología , Micetoma/parasitología , Micetoma/patología , Reacción en Cadena de la Polimerasa , ARN Bacteriano/genética , ARN Ribosómico 16S/genética
15.
BMC Health Serv Res ; 15: 412, 2015 Sep 24.
Artículo en Inglés | MEDLINE | ID: mdl-26399233

RESUMEN

BACKGROUND: In low-incidence countries, most tuberculosis (TB) cases occur among migrants and are caused by reactivation of latent tuberculosis infection (LTBI) acquired in the country of origin. Diagnosis and treatment of LTBI are rarely implemented to reduce the burden of TB in immigrants, partly because the cost-effectiveness profile of this intervention is uncertain. The objective of this research is to perform a review of the literature to assess the cost-effectiveness of LTBI diagnosis and treatment strategies in migrants. METHODS: Scoping review of economic evaluations on LTBI screening strategies for migrants was carried out in Medline. RESULTS: Nine studies met the inclusion criteria. LTBI screening was cost-effective according to seven studies. Findings of four studies support interferon gamma release assay as the most cost-effective test for LTBI screening in migrants. Two studies found that LTBI screening is cost-effective only if carried out in immigrants who are contacts of active TB cases. DISCUSSION AND CONCLUSIONS: Our findings support the cost-effectiveness of LTBI diagnostic and treatment strategies in migrants especially if they are focused on young subjects from high incidence countries. These strategies could represent and adjunctive and synergistic tool to achieve the ambitious aim of TB elimination.


Asunto(s)
Tuberculosis Latente/diagnóstico , Tuberculosis Latente/tratamiento farmacológico , Tamizaje Masivo/economía , Migrantes , Prueba de Tuberculina/economía , Enfermedades Transmisibles , Análisis Costo-Beneficio , Atención Odontológica , Femenino , Humanos , Incidencia , Ensayos de Liberación de Interferón gamma/economía , Masculino , Tuberculosis/epidemiología
17.
Scand J Infect Dis ; 45(4): 320-3, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23113733

RESUMEN

We describe a patient with severe psoriasis and hepatitis C simultaneously treated with pegylated interferon alpha (peg-IFNα) plus ribavirin and etanercept, whose skin lesions improved and who reached a sustained virological response. This case suggests that refractory psoriasis can today no longer be considered as a contraindication for combined hepatitis C virus treatment.


Asunto(s)
Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/uso terapéutico , Psoriasis/tratamiento farmacológico , Psoriasis/virología , Antivirales/uso terapéutico , Contraindicaciones , Etanercept , Humanos , Inmunoglobulina G/uso terapéutico , Masculino , Persona de Mediana Edad , Receptores del Factor de Necrosis Tumoral/uso terapéutico , Ribavirina/uso terapéutico
18.
Mediterr J Hematol Infect Dis ; 15(1): e2023028, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37180207

RESUMEN

The use of specific inhibitory drugs of intracellular signalling pathways (such as Bruton-Kinase inhibitors) for the treatment of Waldenström's macroglobulinaemia (WM) is a recognised risk factor for Aspergillus spp. infections. The overlapping clinical manifestations of the two diseases may require the involvement of different medical specialities. We describe the clinical course of a patient with pulmonary and encephalic aspergillosis, with concomitant orbital infiltration, which represented a difficult diagnosis: the case required a multidisciplinary approach to define the ocular lesions and an in-depth study of the literature.

19.
Intern Emerg Med ; 18(3): 821-830, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36853393

RESUMEN

More than 11.5 billion COVID-19 vaccine doses have been administered around the world. Although vaccine effectiveness for severe infections is reported to be 89.0%, breakthrough infections are common and may lead to severe outcome in fragile population. We conducted a real-world observational study on 420 COVID-19 admitted patients from July 2021 to January 2022 in a tertiary level Italian hospital. We collected patient's vaccination and SARS-CoV-2 serological status, SARS-CoV-2 treatments, oxygen supports, intensive (ICU) and subintensive (sub-ICU) care unit admissions, length of staying (LoS) and in-hospital mortality. One-hundred-seventy-two vaccinated and 248 unvaccinated patients were admitted during the study period. Vaccinated group (Vg) had a significantly more elevated Charlson Comorbidity Index than Unvaccinated group (UVg), and no statistical differences were found in terms of in-hospital mortality, LoS or ICU and sub-ICU admissions. Among Vg, anti-S antibodies were detected in 86.18% of patients (seropositives). Vaccinated seronegative patients' in-hospital mortality was significantly higher than vaccinated seropositive patients (33.33% vs 10.69%, p = 0.0055): in particular, mortality rate in 45-69 years old population was higher in vaccinated seronegative group, and comparable in patients ≥ 70 years old. No differences in terms of outcome were registered between Vg and UVg, taking into account that Vg was considerably older and with more comorbidities. In line with other recent observations, higher mortality rate was evidenced for seronegative vaccinated patients. Primary prophylaxis and early treatments result to be necessary, especially for older and immunosuppressed populations.


Asunto(s)
COVID-19 , Humanos , Persona de Mediana Edad , Anciano , COVID-19/prevención & control , Vacunas contra la COVID-19 , SARS-CoV-2 , Hospitales Universitarios , Italia/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA